Table 3.
NCT Number | Study Title | Phase | Completion of Study | Current state |
---|---|---|---|---|
NCT04977453 | GI-101 as a Single Agent or in Combination with Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors |
Phase 1 Phase 2 |
September 2024 | Recruiting |
NCT05498805 | PD-1 Inhibitors with or Without Radiation in Advanced Melanoma | Phase 2 | August 15, 2025 | Not yet recruiting |
NCT03969004 | Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma | Phase 3 | February 28, 2027 | Recruiting |
NCT04879654 | Toripalimab Combined with Radiotherapy and Chemotherapy in the Treatment of SNMM After Endoscopic Surgery | Phase 2 | May 1, 2026 | Recruiting |
NCT01319565 | Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12 Gy Total Body Irradiation (TBI… | Phase 2 | June 1, 2025 | Active, not recruiting |
NCT02806258 | Comparing Sequential Neoadjuvant Treatment Including Chemotherapy and Accelerated Radiation Focused to the Tumor Bed vs Neoadjuvant Chemotherapy Alone |
Phase 1 Phase 2 |
December 2025 | Recruiting |
NCT03025724 | Photodynamic Therapy for Treatment of Cutaneous Squamous Cell Carcinoma in Situ | N/A | January 2020 | Unknown |
NCT05359419 | Comparison of Two Modes of Photodynamic Therapy for the Treatment of Actinic Keratosis on the Upper Extremities | Phase 4 | December 30, 2023 | Not yet recruiting |
NCT03110159 | DUSA: Cyclic PDT for the Prevention of AK & NMSC in Solid Organ Transplant Recipients |
Phase 1 Phase 2 |
January 2022 | Recruiting |